Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients

J. Jassem, E. Jassem, A. Badzio, G. Kobierska, A. Szymanowska, M. Skrzypski, J. Skokowski, M. Zylicz (Gdansk, Poland)

Source: Annual Congress 2002 - Thoracic oncology: biology
Session: Thoracic oncology: biology
Session type: Poster Discussion
Number: 1504
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Jassem, E. Jassem, A. Badzio, G. Kobierska, A. Szymanowska, M. Skrzypski, J. Skokowski, M. Zylicz (Gdansk, Poland). Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients. Eur Respir J 2002; 20: Suppl. 38, 1504

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 230s
Year: 2001

Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 18s
Year: 2001

How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015



Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011


Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012


K-RAS oncogenic mutations in patients with nonsmall cell lung cancer
Source: Annual Congress 2007 - Biology of thoracic malignancies
Year: 2007


p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance
Source: Eur Respir J 2001; 18: Suppl. 33, 230s
Year: 2001

Management of EGFR mutated nonsmall cell lung carcinoma patients
Source: Eur Respir J 2015; 45: 1132-1141
Year: 2015



MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002

Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005

p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009

Frequency of T790M substitution in exon 20 of EGFR gene in brain metastases in chemotherapy-naive non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012


Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort
Source: Eur Respir J 2012; 40: 177-184
Year: 2012



Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013

EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014

Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010

Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010


Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2004; 24: Suppl. 48, 78s
Year: 2004

A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018



Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012